Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05527951
Other study ID # 2021-77
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 3, 2022
Est. completion date December 31, 2022

Study information

Verified date July 2022
Source Shanghai Mental Health Center
Contact Jun Chen, M.D., Ph.D
Phone 021-34773367
Email doctorcj2010@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Measurement-based care (MBC) is an evidence-based practice that incorporates routine outcome assessment using validated rating scales to guide collaborative clinical decision-making. Although MBC results in improved outcomes for patients with major depressive disorder (MDD), there are barriers to its broad implementation in clinical settings. The use of "enhanced" MBC (eMBC), with mobile apps that allow patients to track outcomes and engage in self-management via WeChat, may address some of these barriers. The investigators hypothesize that implementation with eMBC using WeChat will be superior to standard MBC implementation using paper-pencil assessments at the clinic, for both implementation and clinical outcomes.


Description:

The investigators present a trial protocol for a 2-arm cluster randomized controlled trial (RCT) with a hybrid implementation-effectiveness design comparing standard MBC implementation versus eMBC implementation with 6-month follow up in 12 mental health centers in Shanghai, China. The eMBC implementation uses a WeChat mini-program that includes outcome tracking using brief questionnaires and self-management lessons supplemented with support by a lay coach via WeChat.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Men or women aged 18-65 years; 2. Participants were diagnosed of unipolar depressive disorder by the treating physician based on accepted diagnostic criteria (e.g., CCMD-3, DSM-IV, DSM-5, ICD-10); 3. Participants are expected to have a smartphone device available and be proficient in using a smartphone; 4. Participants should have a junior high school education or above, have sufficient audio-visual skills, be able to fully understand the research content and have the legal ability to sign informed consent. Exclusion Criteria: 1. Presence of obvious violent aggressive behavior or tendencies; 2. Participants who are unstable during onset episodes and cannot cooperate in completing the study content; 3. Serious suicidal tendencies; 4. Inability to carry out effective verbal communication; 5. No smartphone; 6. Other circumstances that prevented cooperation or completion of the study.

Study Design


Intervention

Other:
eMBC
The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
standard MBC
The control intervention group will implement standard MBC using paper and pencil questionnaires.

Locations

Country Name City State
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (12)

Lead Sponsor Collaborator
Shanghai Mental Health Center Boston University, Hongkou Mental Health Center, Institute of Population Research, Peking University, Queen's University, Shanghai CDC for Mental Health, University of Alberta, University of British Columbia, University of California, University of Melbourne, University of Michigan, University of Toronto

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient Health Questionnaire-9 (PHQ-9) To evaluate the severity of depressive symptoms by patients. Remission: total score = 4. up to 6 months
Primary Proportion of patients with a Patient Health Questionnaire-9 (PHQ-9) score Proportion of patients with a PHQ-9 score entered in the clinical record. up to 6 months
Secondary Patient Health Questionnaire-9(PHQ-9) change scores The changes in PHQ-9 scores and depression categories were determined by subtracting the final PHQ-9 score from the initial PHQ-9 score. Therefore, a negative change in PHQ-9 represents a lessening of depression symptoms while a positive change in PHQ-9 represents an increase in depression symptoms. up to 6 months
Secondary The Sheehan disability scale (SDS) To evaluate the functional impairment, including work/study, daily life and family responsibility. The score of each subscale ranged from 0 to 10 which means from no impairment to loss of function. up to 6 months
Secondary Quality of Life scale (QOL-6) To evaluate the quality of life in patients with MDD. The higher the total score, the better the quality of life. up to 6 months
Secondary EuroQoL 5 Dimensions (EQ-5D) To evaluate the quality of life in patients with MDD. The higher the total score, the better the quality of life. up to 6 months
Secondary Health economic assessment (HEA) To evaluate the health services utilization. Economic outcomes will include health service utilization data (both mental health- and non-mental health-related) from the HEA and from available EMR/chart records, including health provider encounters, emergency room visits, hospitalizations, diagnostic tests, and prescriptions. up to 6 months
Secondary Patient Adherence Questionnaire(PAQ) To evaluate the medication adherence.The PAQ is a two item measure, with the first question assessing level of adherence (quantified as number of days in the past week in which medication was not taken) and item 2 assesses reasons for non-adherence. up to 6 months
Secondary Scale To Assess Therapeutic Relationships in Community Mental Health Care (STAR-P) To assess the therapeutic relationship between patients and clinicians in community mental health care settings.It contains 12 items and each item is rated on a 5-point Likert scale, with answers ranging from 0 to 4. up to 6 months
Secondary Proportion of patients who accessed the WeChat Easy to Recover from Depression Mini-Program at least once Proportion of patients who accessed the WeChat Easy to Recover from Depression Mini-Program at least once. up to 6 months
Secondary Proportion of patients who completed at least 4 of 6 lessons in Come Back mini-program Proportion of patients who completed at least 4 of 6 lessons in the Come Back mini-program.Come Back mini-program is a part of the WeChat Easy to Recover from Depression Mini-Program,which consists of 6 weekly lessons based on cognitive-behavioural therapy (CBT) principles. up to 6 months
Secondary System Usability Scale To evaluate patient satisfaction by qualitative interviews.Participants are asked to score 10 items with one of five responses that range from Strongly Agree to Strongly disagree. up to 6 months
Secondary Evidence Based Practice Attitude Scale (EBPAS) To evaluate clinician satisfaction by qualitative interviews.Participants are asked to score 15 items with one of five responses that range from Not at All to To a Very Great Extent. up to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT04422652 - Combination of Novel Therapies for CKD Comorbid Depression Phase 2